Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM72DU3)

Drug Name

DZD9008 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting EGFR Exon20ins mutant (EGFR Exon20ins)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mobocertinib	DMFWE9S	Non-small-cell lung cancer	2C25	Approved	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
EGFR Exon20ins mutant (EGFR Exon20ins)	TT2M7YX	EGFR_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03974022) Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Dizal Pharmaceuticals.
3	Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Feb 25;candisc.1683.2020.